Podcasts

Real-World Decision Points in Biomarker-Driven NSCLC Management

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft discusses how longitudinal biomarker assessment can support treatment planning, resistance evaluation, and rebiopsy decision-making in NSCLC. Key topics include disease progression, tissue limitations, prior assay results,...

Dr Jamie Chaft discusses how...

08/05/2026

Oncology

Podcasts

Connecting the Dots: How MET Fits Into Comprehensive Molecular Profiling

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft reviews the biological and clinical differences among MET biomarkers in NSCLC, emphasizing the importance of matching the specific biomarker question to the appropriate assay. The discussion covers NGS, IHC, and FISH, as well...

Dr Jamie Chaft reviews the...

08/05/2026

Oncology

Podcasts

Testing Matters: Practical Approaches to Biomarker Evaluation in NSCLC

08/05/2026

Jamie Chaft, MD

Dr Jamie Chaft reviews the importance of early tissue stewardship in NSCLC, including how biopsy planning, tissue adequacy, and coordination across the care team can influence biomarker testing and treatment planning. The discussion...

Dr Jamie Chaft reviews the...

08/05/2026

Oncology

Podcasts

Experienced Dermatologists Continue to Outperform Artificial Intelligence in Skin Cancer Diagnosis

08/04/2026

Luc Thomas, MD, PhD

Luc Thomas, MD, PhD, discusses findings from a real-world study comparing artificial intelligence models with clinicians for skin cancer diagnosis, highlighting the strengths and limitations of artificial intelligence and reinforcing the...

Luc Thomas, MD, PhD, discusses...

08/04/2026

Oncology

Podcasts

Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma

07/08/2026

Umberto Vitolo, MD

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell...

Umberto Vitolo, MD, discusses...

07/08/2026

Oncology

Podcasts

How is ctDNA MRD Testing Used in Lymphoma Care?

07/06/2026

David Russler-Germain, MD, PhD

This podcast examines the clinical utility of ctDNA-based MRD testing in diffuse large B-cell lymphoma, focusing on its role in post-treatment risk stratification, relapse detection, and treatment decision-making. Dr David Russler-Germain...

This podcast examines the...

07/06/2026

Oncology

Podcasts

What Is ctDNA MRD Testing and How Does It Work?

07/06/2026

David Russler-Germain, MD, PhD

This podcast explores the principles and clinical applications of circulating ctDNA-based MRD testing in diffuse large B-cell lymphoma, including how personalized sequencing assays can detect microscopic residual disease with greater...

This podcast explores the...

07/06/2026

Oncology

Podcasts

How Are We Detecting Residual Disease in Lymphoma Today?

07/06/2026

David Russler-Germain, MD, PhD

This podcast explores the...

07/06/2026

Oncology

Podcasts

Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia

06/05/2026

Elias Jabbour, MD

Elias Jabbour, MD, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute...

Elias Jabbour, MD, discusses...

06/05/2026

Oncology

Podcasts

Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG)

01/02/2026

Cassie Kline, MD, MAS

Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...

Dr Cassie Klein presents a...

01/02/2026

Oncology

Recent News

News

IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma

08/05/2026

Stephanie Holland

A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...

A phase 2 trial demonstrated...

08/05/2026

Oncology

News

HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma

08/05/2026

Stephanie Holland

Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...

Topline results from a global...

08/05/2026

Oncology

FDA Approval

FDA Approves Rituximab Biosimilar for the Treatment of B-Cell Malignancies and Autoimmune Diseases

08/04/2026

Stephanie Holland

The FDA has approved a rituximab biosimilar referencing Rituxan for multiple hematologic malignancies and autoimmune diseases. Approval was supported by a comprehensive biosimilar development program demonstrating high similarity and no...

The FDA has approved a rituximab...

08/04/2026

Oncology

FDA Alerts

FDA Advisory Committee Backs RP1 Plus Nivolumab for Advanced Melanoma in 10-3 Vote

07/31/2026

Stephanie Holland

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that efficacy findings from the phase 2 IGNYTE trial of RP1 (vusolimogene oderparepvec) plus nivolumab are clinically meaningful, supporting the investigational...

The FDA's Cellular, Tissue, and...

07/31/2026

Oncology

FDA Alerts

Subcutaneous Amivantamab Receives FDA Priority Review for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/30/2026

Emily Estrada

The FDA granted Priority Review to subcutaneous amivantamab and hyaluronidase for previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma, supported by results from the phase 1b/2 OrigAMI-4 trial.

The FDA granted Priority Review...

07/30/2026

Oncology

News

Regorafenib Producess High Response and Durable Disease Control in KIT-Mutant Advanced Melanoma

07/29/2026

Stephanie Holland

The phase 2 RegoMel trial demonstrated that continuous daily regorafenib produced clinically meaningful antitumor activity in heavily pretreated advanced melanoma, with particularly high response rates in KIT-mutant disease and encouraging...

The phase 2 RegoMel trial...

07/29/2026

Oncology

News

Ceralasertib Plus Durvalumab Demonstrates Limited Activity in PD-L1-Resistant Advanced Melanoma

07/29/2026

Stephanie Holland

The phase 2 MONETTE trial found that ceralasertib, administered alone or in combination with durvalumab, produced low response rates in patients with anti–PD-L1-resistant advanced melanoma, while exploratory analyses identified higher...

The phase 2 MONETTE trial found...

07/29/2026

Oncology

News

Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors

07/28/2026

Emily Estrada

A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...

A real-world study found that...

07/28/2026

Oncology

News

Real-World Study Highlights Evolving Treatment Patterns and Petsistent Diagnostic Challenges in Patients With Desmoid Tumors

07/28/2026

Emily Estrada

Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...

Real-world findings demonstrated...

07/28/2026

Oncology

News

Real-World Analysis Identifies Performance Status as a Key Predictor of Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer

07/28/2026

Stephanie Holland

Results from the largest real-world analysis of tarlatamab to date demonstrated that baseline performance status was a major determinant of clinical outcomes in patients with previously treated extensive-stage small cell lung cancer, whereas...

Results from the largest...

07/28/2026

Oncology